Cardiac

1. **AFFIRM** – A comparison of rate control and rhythm control in patients with atrial fibrillation
2. **RACE 2** – Lenient versus Strict Rate Control in Patients with Atrial Fibrillation (see also **RACE 1**)
3. **RACE 7 ACWAS** – Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation
4. **COMPASS** – Rivaroxaban with or without Aspirin in Stable Coronary Artery Disease
5. **AUGUSTUS** - Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
6. **PIONEER-AF-PCI** – Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
7. **WOEST** – What is Optimal Antiplatelet and Anticoagulant Therapy in Patients with Oral Anticoagulation and Coronary Stenting
8. **RE-DUAL PCI** – DAPT with Dabigatran after PCI in Atrial Fibrillation
9. **OAC-ALONE** – Open-Label Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet in Patients with Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation
10. **STOPDAPT-2** – Short and Optimal Duration of DAPT after Everolimus-Eluting Cobalt-Chromium Stent-2
11. **SMART-CHOICE** – Effect of P2Y12 Inhibitor Monotherapy vs DAPT on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention
12. **AFIRE** – Antithrombotic Therapy for Atrial Fibrillation with Stable CAD
13. **CASTLE-AF** – Catheter Ablation for Atrial Fibrillation with Heart Failure
14. **CAPTAF** – Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients with Atrial Fibrillation
15. **CABANA** – Catheter Ablation versus Antiarrhythmic Drug Therapy in Atrial Fibrillation
16. **COMPLETE** – Complete Revascularization with Multivessel PCI for Myocardial Infarction
17. **EXCEL** – 5 Year Outcomes after PCI or CABG for Left Main Coronary Disease
18. **ISCHEMIA** – International Study of Comparative Health Effectiveness with Medical and Invasive Approaches
19. **NOBLE** – Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomized, open-label, non-inferiority trial
20. **SYNTAX** – Percutaneous Coronary Intervention versus CABG for Severe CAD
21. **ISAR-REACT-5** – Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
22. **THEMIS** – Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
23. **BRIDGE** – Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
24. THEMIS – Ticagrelor in Patients with Stable Coronary Artery Disease and Diabetes  
25. GALILEO – A Controlled Trial of Rivaroxaban after Transcatheter Aortic Valve Replacement  
26. GALILEO-4D – Reduced Leaflet Motion after Transcatheter Aortic Valve Replacement  
27. EVOLUT LOW RISK – Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients  
28. PARTNER 3 – Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients  
29. HYPERION – Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm  
30. TTM – Target Temperature Management at 33°C versus 36°C after Cardiac Arrest  
31. TWILIGHT – Ticagrelor with or without Aspirin in High-Risk Patients after PCI  
32. CHARM – Mortality and Morbidity Reduction with Candesartan in Patients with Chronic Heart Failure and Left Ventricular Systolic Dysfunction  
33. TOPCAT – Spironolactone for Heart Failure with Preserved Ejection Fraction  
34. DOSE-AHF – Diuretic Strategies in Patients with Acute Decompensated Heart Failure  
35. PARAGON-HF – ANRI in HF with Preserved Ejection Fraction  
36. PIONEER-HF – ANRI in Acute Decompensated Heart Failure  
37. DAPA-HF – Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction  
38. EMPA-REG OUTCOME – Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes  
39. EVALUATE-HF – Effect of Sacubitril-Valsartan versus Enalapril on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction  
40. PARAMOUNT – The angiotensin receptor neprilysin inhibitor LCZ696 in heart with preserved ejection fraction: a phase 2 double-blind randomized controlled trial  
41. DECLARE-TIMI 58 – Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes  
42. SPRINT – A Randomized Trial of Intensive versus Standard Blood Pressure Control  
43. ODYSSEY OUTCOMES – Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome  
44. ASCEND – Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus  
45. ASPEREE – Effects of Aspirin on Disability-free Survival in the Healthy Elderly  
46. ARRIVE – Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomized, double-blind, placebo-controlled trial  
47. ALLHAT – Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial  
48. PROSPER – Pravastatin in elderly individuals at risk of vascular disease  
49. PROVE-IT TIMI 22 – Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes  
50. JUPITER – Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein  
51. REDUCE-IT – Cardiovascular Risk Reduction with Icosapent Ethyl (Vascepa) for Hypertriglyceridemia  
52. IMPROVE-IT – Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Gastrointestinal
1. **SUP-ICU** – Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU

Infectious Disease
1. **OVIVA** – Oral versus Intravenous Antibiotics for Bone and Joint Infection
2. **POET** – Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis

Nephrology
1. **CREDENCE** - Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
2. **SALT-1** – Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia
3. **SMART** – Balanced Crystalloids versus Saline in Critically Ill Adults

Neurology
1. **DAWN** – Thrombectomy 6-24 Hours after Stroke with a Mismatch between Deficit and Infarct
2. **DEFUSE 3** – Thrombectomy for Stroke at 6-16 hours with Selection by Perfusion Imaging
3. **Treat Stroke to Target** – A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
4. **EXTEND** – Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
5. **MR RESCUE** – A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke
6. **ENCHANTED** – Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke
7. **POINT** – Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
8. **SPARCL** – High-dose Atorvastatin after Stroke or Transient Ischemic Attack

Oncology
1. **KEYNOTE-189** – Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

VTE
1. **ARTEMIS** – Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism
2. **PEgED** – Diagnosis of Pulmonary Embolism with D-Dimer Adjusted to Clinical Probability
3. **PREVENT** – Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis
4. **CLOTS3** – The Clots in Legs or Stockings after Stroke trial: a RCT to determine whether or not IPC reduces the risk of post-stroke DVT and to estimate its cost-effectiveness
5. **REVERSE-AD** – Idracuzimab for Dabigatran Reversal – Full Cohort Analysis
Critical Care/Pulmonology

1. ACURASYS – Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome
2. ROSE – Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome
3. IMPACT – Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
5. CITRIS-ALI – Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients with Sepsis and Severe Acute Respiratory Failure
6. SEPSIS-ACT – Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients with Septic Shock
7. VITAMINS – Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients with Septic Shock